RU2603094C2 - Новый способ получения дифференцированных клеток - Google Patents
Новый способ получения дифференцированных клеток Download PDFInfo
- Publication number
- RU2603094C2 RU2603094C2 RU2012114427/10A RU2012114427A RU2603094C2 RU 2603094 C2 RU2603094 C2 RU 2603094C2 RU 2012114427/10 A RU2012114427/10 A RU 2012114427/10A RU 2012114427 A RU2012114427 A RU 2012114427A RU 2603094 C2 RU2603094 C2 RU 2603094C2
- Authority
- RU
- Russia
- Prior art keywords
- cells
- gene
- myc
- genes
- megakaryocytic
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims abstract description 467
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 221
- 230000004069 differentiation Effects 0.000 claims abstract description 92
- 230000014509 gene expression Effects 0.000 claims abstract description 89
- 210000000601 blood cell Anatomy 0.000 claims abstract description 68
- 210000003593 megakaryocyte Anatomy 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 53
- 108700020796 Oncogene Proteins 0.000 claims abstract description 31
- 239000002243 precursor Substances 0.000 claims abstract description 31
- 101100297420 Homarus americanus phc-1 gene Proteins 0.000 claims abstract description 11
- -1 Ring1a Proteins 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 4
- 101150112512 CBX7 gene Proteins 0.000 claims abstract 10
- 101100297421 Homarus americanus phc-2 gene Proteins 0.000 claims abstract 10
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 claims abstract 10
- 101150062997 Rnf2 gene Proteins 0.000 claims abstract 10
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 claims abstract 2
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 claims description 44
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 41
- 108091057508 Myc family Proteins 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000005138 cryopreservation Methods 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000006911 nucleation Effects 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 abstract description 110
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 5
- 230000003394 haemopoietic effect Effects 0.000 abstract description 3
- 108700024542 myc Genes Proteins 0.000 abstract 2
- 238000000605 extraction Methods 0.000 abstract 1
- 101150062914 BMI1 gene Proteins 0.000 description 27
- 239000013598 vector Substances 0.000 description 24
- 230000012010 growth Effects 0.000 description 21
- 230000006698 induction Effects 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 19
- 210000000267 erythroid cell Anatomy 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 230000032683 aging Effects 0.000 description 15
- 210000003013 erythroid precursor cell Anatomy 0.000 description 13
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 101150085741 Hoxa2 gene Proteins 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
- 229960005309 estradiol Drugs 0.000 description 10
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 9
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 102000006495 integrins Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007420 reactivation Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 5
- 101150039798 MYC gene Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000001902 propagating effect Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102100039542 Homeobox protein Hox-A2 Human genes 0.000 description 3
- 101000962636 Homo sapiens Homeobox protein Hox-A2 Proteins 0.000 description 3
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 3
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 229960003569 hematoporphyrin Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 101000981881 Brevibacillus parabrevis ATP-dependent glycine adenylase Proteins 0.000 description 2
- 101000981889 Brevibacillus parabrevis Linear gramicidin-PCP reductase Proteins 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101150024689 OST3 gene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000973887 Takayama Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003975 mesenteric artery Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000001054 red pigment Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- YQNRVGJCPCNMKT-JLPGSUDCSA-N 2-(4-benzylpiperazin-1-yl)-n-[(2-hydroxy-3-prop-2-enyl-phenyl)methylideneamino]acetamide Chemical compound OC1=C(CC=C)C=CC=C1\C=N/NC(=O)CN1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-JLPGSUDCSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 1
- 101001133600 Homo sapiens Pituitary adenylate cyclase-activating polypeptide type I receptor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 101000652321 Homo sapiens Protein SOX-15 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100020679 Krueppel-like factor 6 Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101150031278 MP gene Proteins 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100519086 Mus musculus Pcgf2 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 101710107770 Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 102100038394 Platelet glycoprotein VI Human genes 0.000 description 1
- 101710194982 Platelet glycoprotein VI Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100030244 Protein SOX-15 Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 108091082327 RAF family Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 101001089018 Ulex europaeus Anti-H(O) lectin 1 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003343 megakaryocytopoietic effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 108700026239 src Genes Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP2009-213645 | 2009-09-15 | ||
| JP2009213645 | 2009-09-15 | ||
| PCT/JP2010/065903 WO2011034073A1 (ja) | 2009-09-15 | 2010-09-15 | 分化細胞の新規製造法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016139042A Division RU2661107C1 (ru) | 2009-09-15 | 2010-09-15 | Новый способ получения дифференцированных клеток |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012114427A RU2012114427A (ru) | 2013-10-27 |
| RU2603094C2 true RU2603094C2 (ru) | 2016-11-20 |
Family
ID=43758674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012114427/10A RU2603094C2 (ru) | 2009-09-15 | 2010-09-15 | Новый способ получения дифференцированных клеток |
| RU2016139042A RU2661107C1 (ru) | 2009-09-15 | 2010-09-15 | Новый способ получения дифференцированных клеток |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016139042A RU2661107C1 (ru) | 2009-09-15 | 2010-09-15 | Новый способ получения дифференцированных клеток |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9200254B2 (enExample) |
| EP (2) | EP3159001B1 (enExample) |
| JP (4) | JP5791191B2 (enExample) |
| KR (2) | KR101834687B1 (enExample) |
| CN (2) | CN102712906B (enExample) |
| AU (1) | AU2010296415B2 (enExample) |
| BR (2) | BR112012005710B1 (enExample) |
| CA (1) | CA2774193C (enExample) |
| DK (2) | DK2500418T3 (enExample) |
| ES (2) | ES2664194T3 (enExample) |
| IN (1) | IN2012DN02642A (enExample) |
| RU (2) | RU2603094C2 (enExample) |
| WO (1) | WO2011034073A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5861191B2 (ja) * | 2010-09-30 | 2016-02-16 | 国立大学法人 熊本大学 | ミエロイド系血液細胞の製造方法 |
| JP5824760B2 (ja) * | 2011-05-13 | 2015-12-02 | 国立大学法人 東京大学 | 多核化巨核球細胞、及び血小板の製造方法 |
| US20140227780A1 (en) | 2011-10-03 | 2014-08-14 | Nissan Chemical Industries, Ltd. | Method for producing megakaryocytes and/or platelets from pluripotent stem cells |
| GB201210857D0 (en) | 2012-06-19 | 2012-08-01 | Cambridge Entpr Ltd | Transcription factor mediated programming towards megakaryocytes |
| EP3973967A1 (en) | 2012-12-21 | 2022-03-30 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| JP6495658B2 (ja) * | 2013-02-08 | 2019-04-03 | 国立大学法人京都大学 | 巨核球及び血小板の製造方法 |
| WO2014168255A1 (ja) * | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 巨核球の成熟化促進物質 |
| US20160060601A1 (en) | 2013-04-17 | 2016-03-03 | Nissan Chemical Industries, Ltd. | Medium composition and method for producing red blood cells using same |
| US10260043B2 (en) * | 2013-05-15 | 2019-04-16 | University Of Rochester | Human extensively self-renewing erythroblasts (ESRE) |
| WO2015199039A1 (ja) | 2014-06-23 | 2015-12-30 | 東亞合成株式会社 | 細胞の多核化を誘導するペプチドおよびその利用 |
| US20180044634A1 (en) | 2015-03-09 | 2018-02-15 | Megakaryon Corporation | Method for Producing Culture Containing Megakaryocytes, and Method for Producing Platelets Using Same |
| RU2730034C2 (ru) * | 2015-04-14 | 2020-08-14 | Киото Юниверсити | Способ получения клона стволовых клеток, пригодного для индуцирования дифференцировки в соматические клетки |
| KR20160129609A (ko) | 2015-04-30 | 2016-11-09 | 삼성전자주식회사 | Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도 |
| ES2833357T3 (es) * | 2015-11-02 | 2021-06-15 | Megakaryon Corp | Procedimiento de preparación de plaquetas con un dispositivo de agitación recíproca |
| JP7350246B2 (ja) | 2016-01-29 | 2023-09-26 | 国立大学法人京都大学 | 血小板産生促進剤のスクリーニング方法 |
| EP3453759B1 (en) | 2016-01-29 | 2023-08-30 | Kyoto University | Platelet production promoter and method of producing platelets using same |
| WO2018164040A1 (ja) | 2017-03-06 | 2018-09-13 | 国立大学法人京都大学 | 血小板の製造方法 |
| FR3068366B1 (fr) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | Procede de production de progeniteurs erythroides |
| EP3650535A4 (en) | 2017-07-07 | 2021-03-17 | Kyoto University | PROCESS AND APPARATUS FOR THE PRODUCTION OF PLATES AND METHOD FOR DETERMINING OPERATING CONDITIONS IN AN APPARATUS FOR THE PRODUCTION OF PLATES |
| WO2019059235A1 (ja) | 2017-09-19 | 2019-03-28 | 株式会社メガカリオン | 精製血小板の製造方法、血小板製剤の製造方法、血液製剤の製造方法、血小板保存液、血小板保存剤および血小板の保存方法 |
| US12091683B2 (en) | 2017-09-19 | 2024-09-17 | Megakaryon Corporation | Method for producing platelets, method for producing platelet product, and method for producing blood product |
| MX2020007071A (es) | 2018-01-05 | 2020-11-11 | Platelet Biogenesis Inc | Composiciones y metodos para producir megacariocitos. |
| WO2020006539A1 (en) | 2018-06-29 | 2020-01-02 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| US20200268839A1 (en) * | 2019-02-25 | 2020-08-27 | National Yang-Ming University | Composition for treating pulmonary fibrosis and emphysema and therapeutic method using the same |
| US20220315895A1 (en) * | 2019-05-01 | 2022-10-06 | Transfusion Health, Llc | Methods of making oligopotent and unipotent precursors |
| EP4074321A4 (en) | 2019-12-12 | 2024-01-03 | National University Corporation Chiba University | Freeze-dried preparation containing megakaryocytes and platelets |
| US20230046238A1 (en) | 2019-12-13 | 2023-02-16 | Megakaryon Corporation | Composition and use thereof |
| JPWO2022092169A1 (enExample) | 2020-10-27 | 2022-05-05 | ||
| JP7716851B2 (ja) * | 2020-12-28 | 2025-08-01 | イビデン株式会社 | 凍結保存液 |
| EP4342982A4 (en) | 2021-06-18 | 2025-05-28 | Megakaryon Corporation | Method for producing multinucleated megakaryocytes with increased platelet production capacity, platelet production method, and blood preparation production method |
| EP4365283A4 (en) | 2021-06-30 | 2025-06-11 | National University Corporation Chiba University | Methods for improving the proliferative properties of common myeloid progenitor cells (CMP) or myelocytic progenitor cells |
| WO2024010317A1 (ko) * | 2022-07-04 | 2024-01-11 | 주식회사 아트블러드 | 유전자 과발현 조합을 이용한 적혈구 분화능이 우수한 불멸화 적혈구전구세포주 확립, 이의 제조방법 및 용도 |
| JP2025534107A (ja) | 2022-10-18 | 2025-10-09 | ソングァン メディカル ファンデーション | 幹細胞から血小板前駆細胞への分化誘導用培地組成物及びそれを用いた分化方法 |
| EP4644539A1 (en) | 2022-12-28 | 2025-11-05 | National University Corporation Chiba University | Method for regulating degree of cell differentiation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2177996C2 (ru) * | 1995-02-02 | 2002-01-10 | ДХУТ Гхази Джасвиндер | Способ получения недифференцированной клетки |
| US20090220465A1 (en) * | 2005-11-07 | 2009-09-03 | The General Hospital Corporation | Methods and compositions for modulation of stem cell aging |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US572333A (en) | 1896-12-01 | Evaporating apparatus | ||
| WO1993000433A1 (en) * | 1991-06-28 | 1993-01-07 | New England Deaconess Hospital | A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors |
| US5723333A (en) | 1995-02-10 | 1998-03-03 | Regents Of The University Of California | Human pancreatic cell lines: developments and uses |
| AU716854B2 (en) * | 1995-02-10 | 2000-03-09 | Regents Of The University Of California, The | Human pancreatic cell lines: developments and uses |
| US20050159378A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| JP4344696B2 (ja) * | 2002-09-27 | 2009-10-14 | バイオイー， インコーポレイテッド | 細胞分離組成物および細胞分離法 |
| JP3896482B2 (ja) * | 2002-10-07 | 2007-03-22 | 独立行政法人産業技術総合研究所 | 分化細胞の作製方法 |
| JP2004350601A (ja) | 2003-05-29 | 2004-12-16 | Tanabe Seiyaku Co Ltd | 霊長類動物の胚性幹細胞から造血系細胞への分化方法 |
| JP4706208B2 (ja) | 2004-08-27 | 2011-06-22 | 株式会社アイル | 造血幹細胞の製造方法 |
| JP2006141356A (ja) | 2004-11-24 | 2006-06-08 | Institute Of Physical & Chemical Research | Ｅｓ細胞から樹立された造血幹細胞 |
| AU2006304392B2 (en) | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| KR101420740B1 (ko) * | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| US8058064B2 (en) | 2006-10-04 | 2011-11-15 | The University Of Tokyo | Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells |
| KR101564044B1 (ko) | 2007-10-31 | 2015-10-28 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 핵초기화 방법 |
| CN101492676B (zh) * | 2008-09-16 | 2011-02-16 | 中国科学院广州生物医药与健康研究院 | 用脑膜细胞生成诱导的多能性干细胞的方法及其用途 |
-
2010
- 2010-09-15 ES ES10817186.9T patent/ES2664194T3/es active Active
- 2010-09-15 RU RU2012114427/10A patent/RU2603094C2/ru active
- 2010-09-15 DK DK10817186.9T patent/DK2500418T3/en active
- 2010-09-15 CN CN201080042161.7A patent/CN102712906B/zh active Active
- 2010-09-15 BR BR112012005710A patent/BR112012005710B1/pt active IP Right Grant
- 2010-09-15 AU AU2010296415A patent/AU2010296415B2/en active Active
- 2010-09-15 KR KR1020167027550A patent/KR101834687B1/ko active Active
- 2010-09-15 US US13/496,321 patent/US9200254B2/en active Active
- 2010-09-15 EP EP16202612.4A patent/EP3159001B1/en active Active
- 2010-09-15 EP EP10817186.9A patent/EP2500418B1/en active Active
- 2010-09-15 ES ES16202612T patent/ES2725688T3/es active Active
- 2010-09-15 CA CA2774193A patent/CA2774193C/en active Active
- 2010-09-15 RU RU2016139042A patent/RU2661107C1/ru active
- 2010-09-15 JP JP2011531940A patent/JP5791191B2/ja active Active
- 2010-09-15 BR BR122013008030A patent/BR122013008030B8/pt active IP Right Grant
- 2010-09-15 DK DK16202612.4T patent/DK3159001T3/da active
- 2010-09-15 CN CN201510530896.9A patent/CN105385659B/zh not_active Expired - Fee Related
- 2010-09-15 WO PCT/JP2010/065903 patent/WO2011034073A1/ja not_active Ceased
- 2010-09-15 KR KR1020127009225A patent/KR101667834B1/ko active Active
- 2010-09-15 IN IN2642DEN2012 patent/IN2012DN02642A/en unknown
-
2015
- 2015-02-13 JP JP2015026547A patent/JP2015130866A/ja active Pending
- 2015-08-03 JP JP2015153048A patent/JP6265437B2/ja active Active
- 2015-10-28 US US14/925,508 patent/US10087419B2/en active Active
-
2016
- 2016-11-29 JP JP2016231020A patent/JP6382917B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2177996C2 (ru) * | 1995-02-02 | 2002-01-10 | ДХУТ Гхази Джасвиндер | Способ получения недифференцированной клетки |
| US20090220465A1 (en) * | 2005-11-07 | 2009-09-03 | The General Hospital Corporation | Methods and compositions for modulation of stem cell aging |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2603094C2 (ru) | Новый способ получения дифференцированных клеток | |
| RU2606764C2 (ru) | Способ получения полиплоидных мегакариоцитов и тромбоцитов | |
| AU2017202019B2 (en) | Novel Method for Producing Differentiated Cells | |
| AU2021361241A1 (en) | Production of megakaryocytes and platelets in a co-culture system | |
| HK1233181A (en) | Novel method for producing differentiated cells | |
| HK1233181A1 (en) | Novel method for producing differentiated cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |